Compare · BDX vs XRAY
BDX vs XRAY
Side-by-side comparison of Becton Dickinson and Company (BDX) and DENTSPLY SIRONA Inc. (XRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and XRAY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 23.6x XRAY ($2.19B).
- Over the past year, BDX is down 2.2% and XRAY is down 23.4% - BDX leads by 21.2 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 7 for XRAY).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- DENTSPLY SIRONA Inc.
- Price
- $189.79-0.43%
- $10.98+0.73%
- Market cap
- $51.69B
- $2.19B
- 1M return
- +19.45%
- -15.70%
- 1Y return
- -2.22%
- -23.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest XRAY
- New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
- EVP & CFO Fortson John C. was granted 24,014 shares (SEC Form 4)
- SVP, CHRO Frohning Andrea L. covered exercise/tax liability with 802 shares, decreasing direct ownership by 1% to 63,191 units (SEC Form 4)
- Amendment: DENTSPLY SIRONA Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Results of Operations and Financial Condition
- SEC Form 10-Q filed by DENTSPLY SIRONA Inc.
- DENTSPLY SIRONA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dentsply Sirona Reports Second Quarter 2026 Results
- Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
- SEC Form 3 filed by new insider Fortson John C.
- Dentsply Sirona to Host Second Quarter Conference Call on August 6th